ArticleScientific reports2025
Innovative vaginal wash formulation with Chitosan nanoparticles targets microbial pathogens, ovarian cancer and inflammation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Pressure-dependent supercritical CO₂ extraction of Heliotropium arbainense: phytochemical enrichment and enhanced antimicrobial, anti-inflammatory, and pro-apoptotic activities.Bioresources and bioprocessing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic microorganisms, ovarian cancer, and inflammation represent significant health challenges, as infections can disrupt the vaginal microbiome, chronic inflammation contributes to cancer progression. This study explored the enhancement of the therapeutic efficacy of vaginal wash (VW) incorporate chitosan nanoparticles (Chit) (VW + Chit) to create a multifunctional formulation targeting microbial infections, inflammation, and ovarian cancer. Gas Chromatography-Mass Spectrometry analysis identified 42 chemical constituents in the vaginal wash, including bioactive alcohols, esters, ethers, and fatty acids, with major components including 1,2-benzenedicarboxylic acid, diethyl ester (24.83%) and Diethylene glycol monododecyl ether (7.10%). Transmission electron microscopy imaging revealed that VW + Chit nanoparticles exhibited improved morphology, reduced agglomeration, and increased particle size (~ 41 nm), indicating successful interaction and encapsulation. Fourier transform infrared spectroscopy confirmed strong intermolecular bonding between chitosan and vaginal wash components, suggesting enhanced structural stability. Antimicrobial testing showed that VW + Chit achieved significantly greater inhibition zones and lower MIC/MBC/MFC values across multiple pathogens, particularly Staphylococcus aureus, Enterococcus faecalis, and Candida albicans, outperforming both its individual components and standard antibiotics. The formulation VW + Chit also demonstrated potent anti-inflammatory activity, with COX-1 and COX-2 inhibition reaching 92.9% and 94.3%, with lowest IC₅₀ values 20.92 ± 0.1 and 9.23 ± 0.1 µg/mL, respectively compared to IC₅₀ values of utilize VW (47.52 ± 0.4 and 43.73 ± 0.1 µg/mL) and Chit alone (27.39 ± 0.1 and 21.67 ± 0.1 µg/mL), respectively. Cytotoxicity assays on SKOV3 ovarian cancer cells revealed that VW + Chit exerted the strongest dose-dependent cytotoxic effect, with the lowest IC₅₀ (147.3 µg/mL) and significant G1 phase cell cycle arrest, indicating antiproliferative potential. In conclusion, the VW + Chit composite shows enhanced antimicrobial, anti-inflammatory, and anticancer activities, highlighting its potential as a novel therapeutic formulation. These findings warrant further investigation through formulation refinement and in vivo studies to validate its clinical applicability for gynecological use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.